These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 35804398)
1. HTA decision-making for drugs for rare diseases: comparison of processes across countries. Stafinski T; Glennie J; Young A; Menon D Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398 [TBL] [Abstract][Full Text] [Related]
2. International comparison of comparative effectiveness research in five jurisdictions: insights for the US. Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289 [TBL] [Abstract][Full Text] [Related]
3. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study. Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843 [TBL] [Abstract][Full Text] [Related]
4. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits? Rawson NSB Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235 [TBL] [Abstract][Full Text] [Related]
5. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now? Menon D; Clark D; Stafinski T Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466 [TBL] [Abstract][Full Text] [Related]
6. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland. Allen N; Walker SR; Liberti L; Salek S Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476 [TBL] [Abstract][Full Text] [Related]
7. A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds. Short H; Stafinski T; Menon D Healthc Policy; 2015 May; 10(4):24-46. PubMed ID: 26142357 [TBL] [Abstract][Full Text] [Related]
8. Historical and projected public spending on drugs for rare diseases in Canada between 2010 and 2025. Lech R; Chow G; Mann K; Mott P; Malmberg C; Forte L Orphanet J Rare Dis; 2022 Oct; 17(1):371. PubMed ID: 36209128 [TBL] [Abstract][Full Text] [Related]
9. Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey. Polisena J; Burgess M; Mitton C; Lynd LD BMC Health Serv Res; 2017 May; 17(1):372. PubMed ID: 28549479 [TBL] [Abstract][Full Text] [Related]
10. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review. Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281 [TBL] [Abstract][Full Text] [Related]
11. Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada. Nagase FNI; Stafinski T; Sun J; Jhangri G; Menon D Orphanet J Rare Dis; 2019 Jun; 14(1):127. PubMed ID: 31174574 [TBL] [Abstract][Full Text] [Related]
12. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples. Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369 [TBL] [Abstract][Full Text] [Related]
13. Influencing Factors of Health Technology Assessment to Orphan Drugs: Empirical Evidence in England, Scotland, Canada, and Australia. Zhou N; Ji H; Li Z; Hu J; Xie JH; Feng YH; Yuan N Front Public Health; 2022; 10():861067. PubMed ID: 35784205 [TBL] [Abstract][Full Text] [Related]
14. A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries. Zozaya N; Villaseca J; Fernández I; Abdalla F; Cadenas-Noreña B; Calleja MÁ; Gómez-Pajuelo P; Mestre-Ferrándiz J; Oliva-Moreno J; Trillo JL; Hidalgo-Vega Á Appl Health Econ Health Policy; 2024 May; 22(3):297-313. PubMed ID: 38214848 [TBL] [Abstract][Full Text] [Related]
15. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand. McCormick JI; Berescu LD; Tadros N Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371 [TBL] [Abstract][Full Text] [Related]
16. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries. Nicod E Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758 [TBL] [Abstract][Full Text] [Related]
17. Do Reimbursement Recommendations by the Canadian Agency for Drugs and Technology in Health Translate Into Coverage Decisions for Orphan Drugs in the Canadian Province of Ontario? Fontrier AM; Kanavos P Value Health; 2023 Jul; 26(7):1011-1021. PubMed ID: 36889379 [TBL] [Abstract][Full Text] [Related]
18. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations. Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664 [TBL] [Abstract][Full Text] [Related]
19. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access? Rawson NSB J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580 [TBL] [Abstract][Full Text] [Related]
20. Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR. Richter T; Janoudi G; Amegatse W; Nester-Parr S Orphanet J Rare Dis; 2018 Feb; 13(1):15. PubMed ID: 29386040 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]